Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3473]

Pimicotinib in TGCT demonstrates durable responses and sustained functional...

Prof Hans Gelderblom - Leiden University, Leiden, Nethrlands

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement ( Prof Hans Gelderblom - Leiden University, Leiden, Nethrlands )

Latest in bladder cancer from the second half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Latest in bladder cancer from the second half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande )

Optimal management of gastric cancers

Dr Prasanth Penumadu - Institution of Cancer Care & Advanced Research...

Optimal management of gastric cancers ( Dr Prasanth Penumadu - Institution of Cancer Care & Advanced Research , Tirupati, India. )

I-DXd shows strong brain metastasis responses in extensive-stage small cell...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Temab-A plus bevacizumab shows promising response rates in advanced colorectal...

Dr Michael Cecchini - Yale School of Medicine, New Haven, USA

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer ( Dr Michael Cecchini - Yale School of Medicine, New Haven, USA )

ESMO 2025: Latest developments in endometrial cancer

Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth

ESMO 2025: Latest developments in endometrial cancer ( Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

PRAME-targeted TCR therapy shows high response rates in metastatic uveal...

Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma ( Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA )

ESMO 2025: Latest in mRCC

Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor...

ESMO 2025: Latest in mRCC ( Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor Grünwald )

More from ecancer